Physician profile
Robert W Schubert
NPI 1245236363
$794.16
in general payments reported to CMS, 2019-2025
10 companies · $16.14 in 2025
The $16.14 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2021: $15.67 · 2022: $149 · 2023: $133 · 2024: $253 · 2025: $16.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $401.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $175.38 | 2023-2024 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.35 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $121.83 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $121.26 | 2019 | |
| Edwards Lifesciences Corporation | $111.21 | 2022 | |
| Abbott Laboratories | $37.75 | 2022 | |
| Glaxosmithkline, LLC. | $32.14 | 2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $28.83 | 2021-2023 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $16.27 | 2023 | Xarelto |
| Abbvie INC. | $16.14 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Schubert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.